膀胱癌是泌尿系统最为常见的恶性肿瘤之一,初次诊断时多为非肌层浸润性膀胱癌(NMIBC)。对于非肌层浸润性膀胱癌(NMIBC)的治疗,经尿道膀胱肿瘤电切术(TURBT)是经典的手术方式。近年来,随着医疗设备的改进及医疗技术的提高,出现了一些新...膀胱癌是泌尿系统最为常见的恶性肿瘤之一,初次诊断时多为非肌层浸润性膀胱癌(NMIBC)。对于非肌层浸润性膀胱癌(NMIBC)的治疗,经尿道膀胱肿瘤电切术(TURBT)是经典的手术方式。近年来,随着医疗设备的改进及医疗技术的提高,出现了一些新型的治疗手段,如经尿道膀胱肿瘤整块切除术、荧光膀胱镜等。TURBT术后常常联合膀胱灌注治疗,常用药物有卡介苗和化疗药物,不过在灌注治疗中对于药物、疗程和剂量的选择目前存在争议。因此,本文就非肌层浸润性膀胱癌(NMIBC)的诊断和治疗进行综述。Bladder cancer is one of the most common malignant tumors of the urinary system. Most of the initial diagnosis is non-muscle invasive bladder cancer (NMIBC). For the treatment of non-muscle invasive bladder cancer (NMIBC), transurethral resection of bladder tumor (TURBT) is a classic surgical method. In recent years, with the improvement of medical equipment and medical technology, some new treatment methods have emerged, such as en-bloc transurethral resection of bladder tumor and fluorescence cystoscopy. TURBT is often combined with intravesical instillation after TURBT. The commonly used drugs are BCG and chemotherapeutic drugs. However, the choice of drugs, course of treatment and dose in intravesical instillation therapy is currently controversial. Therefore, this article reviews the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC).展开更多
目的:探讨术前血清叉头框蛋白O1(Fork head box protein O1,FoxO1)和脂肪酸转运蛋白4(fatty acid-binding protein 4,FABP4)与非肌层浸润性膀胱癌(Non-muscle invasive bladder cancer,NMIBC)患者灌注治疗疗效的关系。方法:选取2021年1...目的:探讨术前血清叉头框蛋白O1(Fork head box protein O1,FoxO1)和脂肪酸转运蛋白4(fatty acid-binding protein 4,FABP4)与非肌层浸润性膀胱癌(Non-muscle invasive bladder cancer,NMIBC)患者灌注治疗疗效的关系。方法:选取2021年1月至2022年10月期间本院收治的68例NMIBC患者作为研究对象。所有患者进行经尿道膀胱肿瘤切除术(Transurethral resection of bladder tumor,TURBT)治疗,患者术后给予表柔比星膀胱灌注。随访12 m,根据最终的病理结果,将患者分为复发组和未复发组。检测对比两组术前血清FOXO1水平和FABP4水平。分析术前血清FABP4水平与TURBT术后膀胱灌注疗效的相关性及诊断价值。结果:68例患者TURBT术后给予表柔比星膀胱灌注,复发率22.1%。复发组术前血清FOXO1水平与未复发组无明显差异(P>0.05);复发组术前血清FABP4水平显著高于未复发组(P<0.05)。以术前血清FABP4水平预测TURBT术后给予表柔比星膀胱灌注治疗后复发的AUC=0.7052。结论:术前血清高FABP4水平提示TURBT术后给予表柔比星膀胱灌注治疗易复发,其用来预测表柔比星膀胱灌注治疗效果有较高价值。展开更多
文摘膀胱癌是泌尿系统最为常见的恶性肿瘤之一,初次诊断时多为非肌层浸润性膀胱癌(NMIBC)。对于非肌层浸润性膀胱癌(NMIBC)的治疗,经尿道膀胱肿瘤电切术(TURBT)是经典的手术方式。近年来,随着医疗设备的改进及医疗技术的提高,出现了一些新型的治疗手段,如经尿道膀胱肿瘤整块切除术、荧光膀胱镜等。TURBT术后常常联合膀胱灌注治疗,常用药物有卡介苗和化疗药物,不过在灌注治疗中对于药物、疗程和剂量的选择目前存在争议。因此,本文就非肌层浸润性膀胱癌(NMIBC)的诊断和治疗进行综述。Bladder cancer is one of the most common malignant tumors of the urinary system. Most of the initial diagnosis is non-muscle invasive bladder cancer (NMIBC). For the treatment of non-muscle invasive bladder cancer (NMIBC), transurethral resection of bladder tumor (TURBT) is a classic surgical method. In recent years, with the improvement of medical equipment and medical technology, some new treatment methods have emerged, such as en-bloc transurethral resection of bladder tumor and fluorescence cystoscopy. TURBT is often combined with intravesical instillation after TURBT. The commonly used drugs are BCG and chemotherapeutic drugs. However, the choice of drugs, course of treatment and dose in intravesical instillation therapy is currently controversial. Therefore, this article reviews the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC).
文摘目的:探讨术前血清叉头框蛋白O1(Fork head box protein O1,FoxO1)和脂肪酸转运蛋白4(fatty acid-binding protein 4,FABP4)与非肌层浸润性膀胱癌(Non-muscle invasive bladder cancer,NMIBC)患者灌注治疗疗效的关系。方法:选取2021年1月至2022年10月期间本院收治的68例NMIBC患者作为研究对象。所有患者进行经尿道膀胱肿瘤切除术(Transurethral resection of bladder tumor,TURBT)治疗,患者术后给予表柔比星膀胱灌注。随访12 m,根据最终的病理结果,将患者分为复发组和未复发组。检测对比两组术前血清FOXO1水平和FABP4水平。分析术前血清FABP4水平与TURBT术后膀胱灌注疗效的相关性及诊断价值。结果:68例患者TURBT术后给予表柔比星膀胱灌注,复发率22.1%。复发组术前血清FOXO1水平与未复发组无明显差异(P>0.05);复发组术前血清FABP4水平显著高于未复发组(P<0.05)。以术前血清FABP4水平预测TURBT术后给予表柔比星膀胱灌注治疗后复发的AUC=0.7052。结论:术前血清高FABP4水平提示TURBT术后给予表柔比星膀胱灌注治疗易复发,其用来预测表柔比星膀胱灌注治疗效果有较高价值。
